Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies
Dateline City:
KENILWORTH, N.J.
Phase 3 VICTORIA Trial is the First Contemporary Outcomes Study Focused Exclusively on a Chronic Heart Failure Patient Population Following a Worsening Event
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the VICTORIA trial, a Phase 3 study evaluating the efficacy and safety of its investigational drug vericiguat, an orally administered soluble guanylate cyclase (sGC) stimulator being developed to treat patients with heart failure with reduced ejection fraction and following a worsening event.
Language:
English
Contact:
Media:
Pamela Eisele, (267) 305-3558
Elizabeth Sell, (267) 305-3877
Investor:
Peter Dannenbaum, (908) 740-1037
Michael DeCarbo, (908) 740-1807
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck
